Raymond James initiated coverage of BioMarin (BMRN) with an Outperform rating and $85 price target BioMarin now trades at a meaningful discount to its large-cap peers, despite credible guidance of meaningful revenue growth and operating leverage, the analyst tells investors in a research note. The concerns over Voxzogo’s near-to-intermediate growth prospects are also “largely overblown”, the firm added. The market has assigned almost no pipeline value, even though the company does have a number of pipeline programs as well as a reasonable level of dry powder for bolt-on deals such as the recently announced Inozyme (INZY) deal, Raymond James stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- AI Analyst Is Bullish on These 3 “Strong Buy” Healthcare Stocks, 9/2/25
- BioMarin Announces Resignation of Chief Accounting Officer
- Positive Outlook on BioMarin Pharmaceutical: Strong Financials and Promising Pipeline Drive Buy Rating
- BioMarin’s Earnings Call: Growth Amid Challenges
- BioMarin price target raised to $114 from $113 at UBS